Publication:
Nevirapine vs efavirenz in virologically supressed patients: Differences in lipoprotein subclasses and inflammatory biomarkers.

dc.contributor.authorEstrada, V
dc.contributor.authorGómez-Garre, M
dc.contributor.authorSantos, J
dc.contributor.authorGutiérrez, F
dc.contributor.authorLabarga, P
dc.contributor.authorPalacios, R
dc.contributor.authorMasiá, M
dc.contributor.authorLópez-Vázquez, M
dc.contributor.authorIsernia, V
dc.contributor.authorVispo, E
dc.contributor.authorFernández-Cruz, A
dc.contributor.authoraffiliation[Estrada,V; Gómez-Garre,M; Isernia,V; Fernández-Cruz A] Hospital Clínico San Carlos, Madrid, Spain. [Santos,J; Palacios,R] Hospital Virgen de la Victoria, Málaga, Spain. [Gutiérrez,F; Masiá,M] Hospital Universitario de Elche, Elche, Spain. [Labarga,P; López-Vázquez,M; Vispo,E] Hospital Carlos III, Madrid, Spain.es
dc.date.accessioned2013-12-05T11:41:37Z
dc.date.available2013-12-05T11:41:37Z
dc.date.issued2012-11-11
dc.description.abstractBackground: The interaction between lipid disturbances and inflammatory markers is not well known in patients on antiretroviral therapy (ART). As nevirapine (NVP) is associated with a better lipid profile than efavirenz (EFV), we investigated the relationships between lipid profiles, lipoprotein subclasses and inflammatory biomarkers in patients with prolonged viral suppression with either NVP or EFV and no obvious clinical inflammation. Methods: 122 clinically stable HIV-infected patients with HIV-1 RNA <20 copies longer than 6 months on NNRTI therapy were studied. 72 (59%) were on EFV and 50 (41%) on NVP. Any potentially inflammatory co-morbid diseases (concurrent viral hepatitis, diabetes, hypertension, chronic liver or renal diseases), or statin treatment, were exclusion criteria. Inflammatory biomarkers included hsCRP, LpPLA2, sCD40L, IL-6, IL-8, t-PA, MCP-1, p-selectin and VCAM-1. Lipoprotein subclass measures (VLDL, LDL, IDL and HDL particle number and size) were obtained by the use of proton nuclear magnetic resonance spectroscopy. Results: 82% were male; median age 45 years. Median CD4 count 550/μL (IQR 324). Median time since HIV diagnosis 96 months (IQR 102) and accumulated time on ART 50 months (IQR 101). Patients on NVP had higher time since HIV diagnosis (126.9 [66.7] vs 91.3 [6.6] months, p=0.008) a prolonged time on ART (89.6 [54.6] vs 62.3 [52.2] months, p=0.01) and were older (47.7 vs 40.7 years, p=0.001) than those on EFV. NVP-treated patients presented increased HDL-c (55.8 [16] vs 48.8 [10.7] mg/dL, p=0.007) and apoA1 levels (153.4 [31.9] vs 141.5 [20.5] mg/dL, p=0.02), and reduced apoB/apoA1 ratio (0.68 [0.1] vs 0.61 [0.1], p=0.003) than EFV-treated patients. No differences in inflammatory markers or lipoprotein subclasses were found between NVP and EFV. In patients with extreme lipid values (less favorable: 75th percentiles of LDL, small/dense LDLp and small HDLp, or more favorable: HDL p75 and apoB/apoA1 ratio p25), no consistent differences in inflammatory biomarkers were found. Conclusions: Patients with prolonged viral suppression on NVP present significantly higher HDL and apoA1 levels and reduced apoB/apoA1 ratios than those on EFV, but no differences were found in lipoprotein particles nor inflammatory biomarkers. Relationships between lipid parameters and inflammatory biomarkers in NNRTItreated patients are complex and do not show a linear relationship in this study.es
dc.description.versionYeses
dc.identifier.citationEstrada V., Gómez-Garre M., Santos J., Gutiérrez F., Labarga P., Palacios R. et al. Nevirapine vs efavirenz in virologically supressed patients: Differences in lipoprotein subclasses and inflammatory biomarkers. Journal of the International AIDS Society. 2012;15(Suppl. 4): 18151es
dc.identifier.doi10.7448/IAS.15.6.18151
dc.identifier.essn1758-2652
dc.identifier.urihttp://hdl.handle.net/10668/1415
dc.journal.titleJournal of the International AIDS Society
dc.language.isoen
dc.publisherBioMed Centrales
dc.relation.publisherversionhttp://www.jiasociety.org/index.php/jias/article/view/18151es
dc.rights.accessRightsopen access
dc.subjectInfecciones por VIHes
dc.subjectNevirapinaes
dc.subjectVIHes
dc.subjectFármacos Anti-VIHes
dc.subjectLipoproteinases
dc.subjectMarcadores Biológicoses
dc.subjectSeropositividad para VIHes
dc.subjectVirus de la Hepatitises
dc.subjectHipertensiónes
dc.subjectDiabetes Mellituses
dc.subjectInhibidores de Transcriptasa Inversaes
dc.subjectImagen por Resonancia Magnéticaes
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infectionses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines::Nevirapinees
dc.subject.meshMedical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIVes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agentses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Lipids::Lipoproteinses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markerses
dc.subject.meshMedical Subject Headings::Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections::HIV Seropositivityes
dc.subject.meshMedical Subject Headings::Organisms::Viruses::Hepatitis Viruseses
dc.subject.meshMedical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellituses
dc.subject.meshMedical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertensiones
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Nucleic Acid Synthesis Inhibitors::Reverse Transcriptase Inhibitorses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Magnetic Resonance Imaginges
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.titleNevirapine vs efavirenz in virologically supressed patients: Differences in lipoprotein subclasses and inflammatory biomarkers.es
dc.typeconference presentation
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Estrada_Nevirapine.pdf
Size:
175.29 KB
Format:
Adobe Portable Document Format
Description:
Abstract pulbicado